M
IMEPro
G62.9 Neurological
Updated March 2026

Polyneuropathy, unspecified

ICD-10 Code: G62.9 · Body Part: Ankle/Foot

QME Evaluation Process

Comprehensive neurological examination, EMG/NCS for length-dependent polyneuropathy, laboratory evaluation to exclude metabolic causes. Impairment per peripheral nerve tables.

Typical Impairment Rating

5-30% LE (2-12% WPI) depending on severity

AMA Guides Edition

5th Edition

Common Treatments

+ Medication management (gabapentin, pregabalin)
+ Physical therapy
+ Pain management

Related Conditions

Body Part Guide

Ankle/Foot Evaluation Guide

Impairment rating methods, common conditions, and QME evaluation protocols

View Guide →

QME Specialties for Polyneuropathy, unspecified

Find a QME Specialist

Browse QME-certified physicians who evaluate polyneuropathy, unspecified and related ankle/foot conditions in California.

Browse Physical Medicine & Rehabilitation Physicians →

Frequently Asked Questions

What is Polyneuropathy, unspecified (G62.9)?

Polyneuropathy, unspecified is an ICD-10 diagnosis code (G62.9) classified under Neurological conditions. It affects the Ankle/Foot and is occasionally seen in California workers' compensation claims. QME physicians evaluate this condition using AMA Guides 5th Edition protocols.

How is G62.9 rated for impairment?

The typical whole person impairment (WPI) range for Polyneuropathy, unspecified is 5-30% LE (2-12% WPI) depending on severity. The exact rating depends on clinical findings, imaging, and the evaluation method (DRE or ROM) chosen by the QME physician per AMA Guides 5th Edition.

What is the QME evaluation process for G62.9?

Comprehensive neurological examination, EMG/NCS for length-dependent polyneuropathy, laboratory evaluation to exclude metabolic causes. Impairment per peripheral nerve tables.

What treatments are common for Polyneuropathy, unspecified?

Common treatments for Polyneuropathy, unspecified include Medication management (gabapentin, pregabalin), Physical therapy, Pain management. Treatment appropriateness and outcomes are considered during the QME evaluation when determining permanent and stationary status and apportionment.